Clinical Trial NU 11C02
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
- Principal Investigator
- Jeffrey Raizer
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.NU 11C02
- The purpose of this study is to determine the effectiveness and safety of combining multiple types of treatments for patients who have recurrent high grade brain tumors.
- Participants in this study have a high grade glioma which has been treated in the past and has recurred. Typically, patients receive one or more of several types of treatments, including radiation therapy, chemotherapy such as temozolomide, and other treatments that circulate through the body, like bevacizumab. All of these treatments have been used in past for patients with glioma, and we think that using all three of these treatments together is safe and may be more effective than using them separately.
Some of the eligibility criteria include:
- Participants must be at least 18 years of age.
- Participants must be diagnosed with glioblastoma or anaplastic glioma.
- Participants must have been previously treated with radiation therapy and temozolomide or radiation therapy, temozolomide and bevacizumab.
- Description of Treatment
- This study will use all three of the above treatments together and may be more effective than using them separately. Participants will receive radiation therapy every weekday for 5 weeks (25 treatments). During radiation therapy, participants will take temozolomide by mouth every day and will receive bevacizumab into a vein in the arm every two weeks. After the radiation is complete participants will continue with additional cycles of the bevacizumab and temozolomide (1 cycle = 8 weeks). Participants will take temozolomide by mouth daily for the first 6 weeks of each cycle, and will receive bevacizumab infusions every two weeks.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jeffrey Raizer
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
- A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
- A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
- An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
- Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer
- A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
- A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
- Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
- Randomized Phase II of Concurrent Bevacizumab & Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
last updated: 04-Sep-15 04:04 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.